Vall d'Hebron Institut de Recerca (VHIR) and Universitat Autònoma de Barcelona (UAB)
Prof. Miguel Chillon
Dr. M. Chillon is an ICREA senior researcher and principal investigator of the UAB-VHIR Joint Unit at the Institute of Neuroscience (UAB) since 2017. Dr. Chillon obtained his Ph.D. in Genetics at Hospital Duran I Reynals and Universitat de Barcelona in 1994 in Barcelona and received the Boehringer Mannheim Award in Human Genetics by the Spanish Association of Human Genetics in 1995, and was a member of the research team awarded the Premio de Investigación Ciudad de Barcelona. Dr. M Chillon is the founder and Director of the Vector Production Unit at UAB a technological platform to produce viral vectors (since 2004), Associated Professor at the Universitat Autònoma de Barcelona (since 2005), Group leader at Vall d'Hebron Hospital Research Institute (VHIR) (since 2017), Member of the Biosafety Committee of the UAB (2006-2018), Member of the Scientific Committee of the UAB (since 2019), Member of the Transfer Committee at VHIR (since 2020), Member of the Governing Board of the Institute of Neurosciences at UAB, since 2020, Coordinator of the Advanced Therapies Tranversal Program at VHIR (since 2020), Scientific advisor of different organizations and spin-off biotechs (SpliceBio, Ninevah, Biointaxis, Klogene Therapeutics, Fundacion La Lucha de Abril, and la Asociación Española de Paraparesia Espástica Familiar (AEPEF)).
Dott. Angel Edo
He is a Biotechnologist with 7+ years of experience in preclinical research. Specialized in the development of gene therapy treatments based on the use of viral vectors for the treatment of neurodegenerative diseases such as multiple sclerosis. He got his Ph.D. in Biochemistry, Molecular Biology and Biomedicine from Vall d’Hebron Institute of Research (VHIR), Autonomous University of Barcelona (UAB). He is currently a Postdoctoral researcher at the Autonomous University of Barcelona (UAB), working with the Group of Gene Therapy for CNS led by Dr. Miguel Chillón (UAB). He is also pursuing a third Master's degree in Clinical Trials Monitoring and Medical Affairs from the Centre for Higher Studies in the Pharmaceutical Industry (CESIF)